Because small peptides have many advantages than monoclonal antibodies (MoAbs)

radio-labeled peptides have emerged as an important class of radiopharmaceuticals and are the subject of doing nuclear medicine research. 188 Re (E β

max =2.11MeV; E γ=155keV; T 1/2 =16.9h) is an attrative therapeutic radionuclide and conveniently obtained on demand by elution from the 188 W/ 188 Re generator system. This article reviewed the physical and chemical properties

nuclear characters and biological behavior in vivo and vitro of the 188 Re. The approaches (direct labeling approach

preconjugate labeling approach

postconjugate labeling approach) to the labeling of peptides radiopharmceuticals were discussed and recent progress of the 188 Re labeled peptides (RC-160

VIP

et al ) were given. The forecasts of 188 Re labeled peptide radiopharmceuticals in their development were considered.